nasdaqbntx
BioNTech had a strong quarter despite slowing COVID sales.A robust pipeline makes it a takeover target for larger pharma companies.A share repurchase program should help support price action in 2023.5 stocks we like better than BioNTechBioNTech (NASDAQ:BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE:PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held ...
ValueWalk
Following is the unofficial transcript of a CNBC interview with Pfizer Inc. (NYSE:PFE) Chairman and CEO Albert Bourla on CNBC’s “Squawk Box” (M-F, 6AM-9AM ET) today, Monday, January 10. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Pfizer CEO Bourla: Omicron-Specific Covid Vaccine Will Be Ready By MarchANDREW ROSS SORKIN: Welcome back to “Squawk Box.” All day today, CNBC brings you the biggest names from the virtual J.P. Morgan Healthcare Conference. Meg Tirrell joins us with another very special guest this morning. Meg. MEG TIRRELL: Andrew, thanks ...
ValueWalk
In hisDaily Market Notes report to investors, while comenting on the tired markets, Louis Navellier wrote: Q1 2021 hedge fund letters, conferences and more Tired Stock MarketsThe stock market is tired and the economic news is perfect. Retail sales, the fact that the fed anticipates inflation to be transitory, the growing bottlenecks everywhere that's going to keep manufacturing strong, the earnings environment. Everything is good. But the market is bored, it seems tired. The economic news, as good as it is, the news coming out of the beltway seems to be distracting investors. The most powerful...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら